These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35773445)

  • 1. A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens.
    Upreti S; Samant M
    Pharm Res; 2022 Sep; 39(9):2119-2134. PubMed ID: 35773445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Overview of COVID-19 vaccines licensed in the EU-from technology via clinical trial to registration].
    Hildt E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1237-1243. PubMed ID: 36257986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
    Zhou Z; Zhu Y; Chu M
    Front Immunol; 2022; 13():898192. PubMed ID: 35669787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking the COVID-19 vaccines: The global landscape.
    Yadav T; Kumar S; Mishra G; Saxena SK
    Hum Vaccin Immunother; 2023 Dec; 19(1):2191577. PubMed ID: 36995773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.
    Marchese AM; Kalkeri R; Vadivale M; Suntronwong N; Toback S; Poovorawan Y
    Expert Rev Vaccines; 2023; 22(1):620-628. PubMed ID: 37386785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covid-19 vaccines and variants of concern: A review.
    Hadj Hassine I
    Rev Med Virol; 2022 Jul; 32(4):e2313. PubMed ID: 34755408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.
    Simões RSQ; Rodríguez-Lázaro D
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.
    Michalik S; Siegerist F; Palankar R; Franzke K; Schindler M; Reder A; Seifert U; Cammann C; Wesche J; Steil L; Hentschker C; Gesell-Salazar M; Reisinger E; Beer M; Endlich N; Greinacher A; Völker U
    Haematologica; 2022 Apr; 107(4):947-957. PubMed ID: 35045692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19: vaccines, efficacy and effects on variants.
    Rudan I; Adeloye D; Sheikh A
    Curr Opin Pulm Med; 2022 May; 28(3):180-191. PubMed ID: 35200162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current status of COVID-19 vaccines. A scoping review.
    Rueda-Fernández M; Melguizo-Rodríguez L; Costela-Ruiz VJ; González-Acedo A; Ramos-Torrecillas J; Illescas-Montes R
    Drug Discov Today; 2022 Nov; 27(11):103336. PubMed ID: 35995361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.
    Rogliani P; Chetta A; Cazzola M; Calzetta L
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33807818
    [No Abstract]   [Full Text] [Related]  

  • 14. Inactivated vaccine Covaxin/BBV152: A systematic review.
    Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S
    Front Immunol; 2022; 13():863162. PubMed ID: 36016940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants.
    Damasceno DHP; Amaral AA; Silva CA; Simões E Silva AC
    Curr Med Chem; 2022; 29(15):2673-2690. PubMed ID: 34473613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
    Zeng B; Gao L; Zhou Q; Yu K; Sun F
    BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous prime-boost strategies for COVID-19 vaccines.
    Sapkota B; Saud B; Shrestha R; Al-Fahad D; Sah R; Shrestha S; Rodriguez-Morales AJ
    J Travel Med; 2022 May; 29(3):. PubMed ID: 34918097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions.
    Francis AI; Ghany S; Gilkes T; Umakanthan S
    Postgrad Med J; 2022 May; 98(1159):389-394. PubMed ID: 37066438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates.
    Mukhopadhyay L; Yadav PD; Gupta N; Mohandas S; Patil DY; Shete-Aich A; Panda S; Bhargava B
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):93-114. PubMed ID: 33361645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.